CRISPR screening in human hematopoietic stem and progenitor cells reveals an enrichment for tumor suppressor genes within chromosome 7 commonly deleted regions

Leukemia ◽  
2022 ◽  
Author(s):  
Jeremy T. Baeten ◽  
Weihan Liu ◽  
Isabelle C. Preddy ◽  
Ningxuan Zhou ◽  
Megan E. McNerney
Hematology ◽  
2005 ◽  
Vol 2005 (1) ◽  
pp. 156-160 ◽  
Author(s):  
A. Thomas Look

Abstract Clonal disorders of hematopoiesis, such as myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD), affect both hematopoietic stem cells and progenitor cells within the erythroid, platelet and granulocytic lineages and can have devastating consequences in children and adults. The genetic features of these diseases often include clonal, nonrandom chromosomal deletions (e.g., 7q–, 5q–, 20q–, 6q–, 11q– and 13q–) that appear to inactivate tumor suppressor genes required for the normal development of myeloid cells (reviewed in Bench1 and Fenaux2). These putative tumor suppressors have proved to be much more difficult to identify than oncogenes activated by chromosomal translocations, the other major class of chromosomal lesions in MDS and MPD.3 Although MDS and MPD are almost certainly caused by mutations in stem/progenitor cells,4 the role of inactivated tumor suppressor genes in this process remains poorly understood. In a small portion of myeloid diseases, mutations have been identified in genes encoding factors known to be required for normal hematopoiesis, such as PU.1, RUNX1, CTNNA1 (α-catenin) and c/EBPα, and implicating these genes as tumor suppressors.5–7 Nonetheless, the identities of most deletion-associated tumor suppressors in these diseases remains elusive, despite complete sequencing of the human genome. The deleted regions detected by cytogenetic methods are generally very large, containing many hundreds of genes, thus making it hard to locate the critical affected gene or genes. It is also unclear whether dysfunctional myelopoiesis results from haploinsufficiency, associated with the deletion of one allele, or from homozygous inactivation due to additional point mutations or microdeletions of the retained wild-type allele. In general MDS have proved surprisingly resistant to conventional treatments. Targeted therapeutic advances in MDS will likely depend on a full comprehension of underlying molecular mechanisms, in particular the tumor suppressor genes lost through clonal, nonrandom chromosomal deletions, such as the 7q– and (del)5q.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 796-796 ◽  
Author(s):  
Windy D. Berkofsk-Fessler ◽  
Jonathan D. Licht ◽  
Melanie-Jane McConnell ◽  
Donna S. Neuberg ◽  
Timothy S. Bowler ◽  
...  

Abstract Polycythemia vera (PV) is a myeloproliferative disease characterized by accumulation of erythrocytes and cells of the myeloid and megakaryocyte lineages. Although genes like PRV-1 and PTP-MEG2 have been implicated in the pathology of PV, there is no consensus on their importance in the disease process. Progenitor cells from PV patients can grow in the absence of erythropoietin, and are hypersensitive to a variety of other growth factors. This suggests that polycythemic hematopoietic progenitor cells possess a significantly different genetic program. We tested this idea by molecular profiling hematopoietic progenitor cells (CD34+) from PV specimens and normal donors. We purified CD34+ cells from the marrow of 10 PV patients and harvested total RNA. Biotinylated cRNA was made through two rounds of linear amplification, and hybridized to Affymetrix HGU133A genechips. CD34+ cells from marrow mononuclear cells of 5 normal controls were processed similarly. The resulting datasets were normalized to the median across chips and across genes. Unsupervised hierarchical clustering showed that PV samples had a distinct gene expression profile from the controls. We then performed supervised clustering using a non-parametric t-test (Wilcoxon rank sum test) using the Benjamini and Hochberg multiple testing correction held to a p-value of 0.01 to determine genes that were significantly different between disease and normal samples. Using these stringent criteria, there were 331 genes that reached significance. Strikingly most of these were decreased in expression compared with control CD34+ cells and only 34 genes were upregulated in PV. A 35 gene predictor set was discovered through the use of a k-nearest neighbor metric. This set was 100% accurate for the prediction of PV in a leave one out cross-validation approach. Among these genes are EVI1, a known oncogene and one of only two genes upregulated in PV on this list, and the putative tumor suppressor genes TUSC4 (NPR2), NDRG1 and KLF4. Also among the predictor genes is BAALC, a gene expressed in normal CD34+ cells and known to be a prognostic indicator gene for acute myeloid leukemia.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 390-390
Author(s):  
Hiroya Asou ◽  
Hirotaka Matsui ◽  
Yuko Ozaki ◽  
Toshiyuki Takemura ◽  
Akiko Nagamachi ◽  
...  

Abstract To isolate myeloid tumor suppressor genes from 7q, we tried to detect microdeletions (< 100 Kb) that might be present in MDS/AML cells carrying apparently normal chromosome 7. For this purpose, we developed our original microarray-based CGH technology. In this system, instead of BAC clones generally used as probes, we applied short (3–5 Kb) genomic DNA fragments containing strictly no repetitive sequences. We made 235 probes in a region spanning 21.7 Mb within 7q21.3–7q31.1. Although we selected MDS/AML patients whose marrow did not show cytogenetically visible 7q deletions, gross copy number changes frequently observed in adult patients prevented us from identification of common microdeletions. By investigation of 21 childhood myeloid leukemia patients with normal karyotype, we successfully identified a common microdeletion spanning approximately 120 Kb. Eight (38%) patients shared this microdeletion, which was not detected in normal individuals. Database search revealed that this region contains three hypothetical genes. Only vertebrates have these genes that likely evolved from one common ancestral gene of fish. Real-time quantitative PCR revealed that 9 (29%) out of 31 adult MDS/AML harbors microdeletions in at least one of these three genes. None of these genes had been well characterized nor has known motifs that would suggest function of the gene products. We named them Miki, Titan and Kasumi. Immunoblot analysis revealed expression of all three genes at high levels in most lymphoid leukemia cell lines, while half of myeloid cell lines lacked at least one of their expression. In leukemia cells carrying monosomy 7, expression levels were generally low. Miki, a heavily glycosylated protein, co-localized with centrosomes and spindles in the mitotic phase. To test the function of Miki, we used si-RNAs to downregulate Miki expression in HeLa and K562 cells, both of which show basically normal metaphase and nuclear morphology. Cells expressing Miki at reduced levels showed small and fragmented centrosomes, loss of spindle tension, tripolar mitosis or even completely disturbed spindle formation. As a result, anaphase lagging, colchicine-mitosis (C-mitosis), premature chromosome decondensation and chromatid bridges were observed in virtually all cells in the mitotic phase. In the interphase, bi- or tri-nuclear or even multinuclear cells with micronuclei, all of which are characteristic to MDS, were frequently observed. On the other hand, proteomic analysis revealed that Titan and Kasumi bind to the DNA-PK complex, which plays critical roles in the non-homologous end joining (NHEJ) of double stranded DNA (dsDNA) breaks. Indeed, these proteins were translocated from cytoplasm to nucleus by ionizing radiation (IR) or by treatment of drugs that yield dsDNA breaks. Cells expressing Kasumi at reduced levels by si-RNA showed increased radiosensitivity, sister chromatid exchange, and number of background-level phosphorylated histone H2AX foci (i.e., foci formed without IR), which are co-localized with dsDNA breaks. These results indicate that the genes we isolated are promising candidates for anti-leukemic genes located in 7q, because downregulation of these gene products by 7q deletions would cause the abnormal morphology of MDS and genetic instability.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 368-368 ◽  
Author(s):  
Deepa Edwin ◽  
Christine McMahon ◽  
Friederike Kreisel ◽  
Molly Bogue ◽  
Timothy S. Fenske ◽  
...  

Abstract The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and cellular dysplasia. Peripheral blood cytopenias and progression to AML are important clinical sequelae of MDS. 10–20% of MDS cases are a consequence of prior treatment with alkylators. The molecular basis of therapy-related MDS (t-MDS) is poorly understood. Point mutations of RAS family members and inactivation of the p53 and p15 tumor suppressor genes by mutation or hypermethylation represent the most frequently reported molecular abnormalities in MDS. Clonal cytogenetic changes, usually involving loss of material from chromosomes 5 and/or 7 are present in &gt;90% of t-MDS cases. These recurring deletions suggest that myeloid tumor suppressor genes may be present in these regions, although their identify has not yet been established. Progress in understanding the genetic basis of human MDS has been hampered by a lack of suitable animal models. To develop a mouse model of t-MDS, we screened 32 inbred strains for susceptibility to t-MDS after treatment with the prototypical alkylating agent, N-nitroso-N-ethylurea (ENU). Mice (n=12 per strain) received two doses of ENU (100mg/kg, IP) or no treatment (n=12 per strain) at 9 and 10 weeks of age. Among the strains tested, SWR/J mice were found to be highly susceptible to myeloid malignancies (MDS/AML). We confirmed this in a second cohort. 10 of 33 (30%) ENU-treated SWR/J mice developed key features of MDS, including anemia (mean Hb=10.9 ±1.1 g/dL, compared to mean Hb=14.0 ±0.3 g/dL in 32 untreated age and sex-matched SWR/J mice, p=0.0006) and erythroid dysplasia (megaloblastic maturation, nuclear budding and blebbing in normoblasts) with a latency of approximately 30 weeks after ENU exposure. There was also evidence of dysplasia in the megakaryocytic lineage, manifested by numerous micromegakaryocytes with unilobar nuclei. Mild dysplastic features were detected rarely in untreated controls from this strain. The t-MDS mice developed significant splenomegaly (mean=0.49 ±0.19 g compared to control mean=0.15 ±0.01 g, p=0.004) with histologic evidence of increased extramedullary hematopoiesis. No significant immunophenotypic differences were detected in bone marrow cells from the t-MDS cases compared to controls. Iron stores were normal with no evidence of ringed sideroblasts. In 2 of the 10 affected mice, MDS evolved to AML, manifested by rapid breathing, circulating myeloid blasts, and leukocytosis (21-621,000 cells/μL). An additional 3 ENU-treated SWR/J mice developed AML without evidence of a preceding MDS phase. All AML cases had a Kit+Gr1+CD34- phenotype with no expression of lymphoid markers. The blasts were myeloperoxidase negative. This mouse model recapitulates many key features of human alkylator-associated t-MDS/AML and should be useful for discovery of mutations involved in the pathogenesis of this syndrome. We are employing array-based comparative genomic hybridization and candidate gene resequencing as tools for mutation discovery in this model. Because of their unique sensitivity to t-MDS, the SWR/J strain will also be particularly useful for identification of germline polymorphisms that affect susceptibility to alkylator-associated t-MDS/AML.


2001 ◽  
Vol 38 (2) ◽  
pp. 139-147
Author(s):  
Jan W. Gratama ◽  
D. Robert Sutherland ◽  
Michael Keeney

Sign in / Sign up

Export Citation Format

Share Document